|
|
Post by compound26 on Oct 9, 2017 11:59:33 GMT -5
|
|
|
|
Post by madog365 on Oct 9, 2017 12:40:15 GMT -5
I thought it was interesting that Charles Mattocks shared this news story seemingly as if talking about Mannkind... slip of the tongue?
|
|
|
|
Post by sportsrancho on Oct 9, 2017 16:28:53 GMT -5
Gotta love him! ^^^
|
|
|
|
Post by buyitonsale on Oct 9, 2017 18:14:49 GMT -5
Giving Amphastar the right of first refusal in China gives MNKD more leverage to negotiate a good deal there.
I think it’s going to be huge 😎
|
|
|
|
Post by frenz on Oct 9, 2017 18:20:54 GMT -5
I thought it was interesting that Charles Mattocks shared this news story seemingly as if talking about Mannkind... slip of the tongue? Yeah, what was up with that? So weird! |
|
|
|
Post by peppy on Oct 9, 2017 18:56:20 GMT -5
MNKD Mike C is way ahead of us?
|
|
|
|
Post by dreamboatcruise on Oct 9, 2017 19:13:54 GMT -5
MNKD Mike C is way ahead of us?
Yes, at this point there must be a question mark, since Mike gave no indication as to what it means to be a "target". It would be nice if he is indeed ahead of what he has told us, having actually achieved something towards getting into Chinese market, but at this point we can only "hope" and speculate. |
|
|
|
Post by afrezzamiracle on Oct 9, 2017 19:38:11 GMT -5
1.379 BILLION population. A hell of a lot of diabetics!
|
|
|
|
Post by brotherm1 on Oct 9, 2017 19:42:18 GMT -5
Giving Amphastar the right of first refusal in China gives MNKD more leverage to negotiate a good deal there. I think it’s going to be huge 😎 Good point. i forgot about this. “6.5 Right of First Refusal in China. In consideration of the amendments contained in this Second Amendment and in the Option Amendment, MannKind hereby grants Amphastar the right of first refusal to participate in the development and commercialization of Afrezza in China through a collaborative arrangement. Specifically, Amphastar and MannKind agree that MannKind will not commence the process of obtaining approval of Afrezza in China without first providing Amphastar with (i) at least ninety (90) days prior written notice of MannKind’s intention to commence the process of obtaining approval of Afrezza in China, and (ii) if Amphastar confirms its interest in collaborating in the development or commercialization of Afrezza in China in writing within thirty (30) days of receipt of MannKind’s notice, then the Parties shall reserve sixty (60) days to negotiate in good faith the terms of such a collaborative arrangement for Afrezza in China. In the event that the Parties are unable to agree on commercial terms for a collaborative agreement after the sixty (60) day negotiation period, then MannKind shall have the right to negotiate a collaborative agreement with another party (“Competing Terms”). MannKind shall present the Competing Terms to Amphastar in writing, and within sixty (60) days of receipt of the Competing Terms, Amphastar shall have the option to either (i) decline to match the Competing Terms, or (ii) agree to match the same Competing Terms and enter into a collaborative agreement with MannKind in China. [ 2.6 Section 10.1 of the Agreement shall be extended until December 31, 2023. All other terms and conditions in paragraph 10.1 shall remain in full force and effect.” www.sec.gov/Archives/edgar/data/1297184/000129718417000007/amph-20161231ex10345c26b.htmu |
|
|
|
Post by joeypotsandpans on Oct 9, 2017 19:54:50 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 9, 2017 20:41:48 GMT -5
Giving Amphastar the right of first refusal in China gives MNKD more leverage to negotiate a good deal there. I think it’s going to be huge 😎 Good point. i forgot about this. “6.5 Right of First Refusal in China. In consideration of the amendments contained in this Second Amendment and in the Option Amendment, MannKind hereby grants Amphastar the right of first refusal to participate in the development and commercialization of Afrezza in China through a collaborative arrangement. Specifically, Amphastar and MannKind agree that MannKind will not commence the process of obtaining approval of Afrezza in China without first providing Amphastar with (i) at least ninety (90) days prior written notice of MannKind’s intention to commence the process of obtaining approval of Afrezza in China, and (ii) if Amphastar confirms its interest in collaborating in the development or commercialization of Afrezza in China in writing within thirty (30) days of receipt of MannKind’s notice, then the Parties shall reserve sixty (60) days to negotiate in good faith the terms of such a collaborative arrangement for Afrezza in China. In the event that the Parties are unable to agree on commercial terms for a collaborative agreement after the sixty (60) day negotiation period, then MannKind shall have the right to negotiate a collaborative agreement with another party (“Competing Terms”). MannKind shall present the Competing Terms to Amphastar in writing, and within sixty (60) days of receipt of the Competing Terms, Amphastar shall have the option to either (i) decline to match the Competing Terms, or (ii) agree to match the same Competing Terms and enter into a collaborative agreement with MannKind in China. [ 2.6 Section 10.1 of the Agreement shall be extended until December 31, 2023. All other terms and conditions in paragraph 10.1 shall remain in full force and effect.” www.sec.gov/Archives/edgar/data/1297184/000129718417000007/amph-20161231ex10345c26b.htmuCould the 90 days have already started? Additionally. Buy in from Amphastar. Possible! |
|
|
|
Post by golfeveryday on Oct 10, 2017 6:21:04 GMT -5
MNKD Mike C is way ahead of us?
Since they first showed this chart, I am most shocked that EU is not identified as a target. Any thoughts why that may be? |
|
|
|
Post by agedhippie on Oct 10, 2017 7:53:55 GMT -5
MNKD Mike C is way ahead of us?
Since they first showed this chart, I am most shocked that EU is not identified as a target. Any thoughts why that may be? At a guess - time and return on investment. For the UK you would need to get it past EMA, NICE, and the regional prescribing committees. That's before you start trying to get doctors to use it. Also drugs sell for only between 10% to 20% of the US price. |
|
|
|
Post by peppy on Oct 10, 2017 7:56:58 GMT -5
Since they first showed this chart, I am most shocked that EU is not identified as a target. Any thoughts why that may be? At a guess - time and return on investment. For the UK you would need to get it past EMA, NICE, and the regional prescribing committees. That's before you start trying to get doctors to use it. Also drugs sell for only between 10% to 20% of the US price. aged, have you bought a few shares here, are you riding this train? the train is about to leave this station.
|
|
|
|
Post by golfeveryday on Oct 10, 2017 7:57:19 GMT -5
Since they first showed this chart, I am most shocked that EU is not identified as a target. Any thoughts why that may be? At a guess - time and return on investment. For the UK you would need to get it past EMA, NICE, and the regional prescribing committees. That's before you start trying to get doctors to use it. Also drugs sell for only between 10% to 20% of the US price. But not having it as a target is odd to me regardless. Every pharma moves into these markets. Was just curious others thoughts. I agree MNKD should focus on markets with fewer barriers to entry. |
|
